STAT | Reporting from the frontiers of health and medicine
www.statnews.com
Santé Bien-être
WHO says Trump’s latest vaccine policy order is misguided
Santé Bien-être
STAT+: Cancer patients face longer wait times to begin treatment, according to new study
Santé Bien-être
Opinion: The Lindsay Clancy case shows the limits of postpartum psychiatry
Santé Bien-être
STAT+: Pharmalittle: We’re reading about Lilly ‘black market’ lawsuits, pushback over Trump vaccine plan, and more
Santé Bien-être
STAT+: The secret AI-startup project I’ve been working on the last six months
Santé Bien-être
STAT+: Definium Therapeutics says its LSD therapy eased anxiety in late-stage trial
Santé Bien-être
STAT+: Biotech company co-founded by top autoimmune researcher lays out plans with antibody therapies
Santé Bien-être
STAT+: Inside a $7 billion Silicon Valley startup’s mad dash to automate the business of health care
Santé Bien-être
Opinion: Climate change is making people with chronic illness even sicker
Santé Bien-être
STAT+: Neurocrine Biosciences rare disease drug possibly tied to safety issues, experts say
Santé Bien-être
Stopping statins in people over 75 at low risk for heart disease didn’t increase deaths
Santé Bien-être
Medicaid will stop paying for some gender-affirming care for transgender minors
Santé Bien-être
STAT+: Trump is counting on the health care industry to remake vaccines. It’s pushing back instead
Santé Bien-être
Opinion: Trump says his executive order should restore trust in vaccines. It does the exact opposite
Santé Bien-être
How we know that splitting up the MMR vaccine could be dangerous
Santé Bien-être
STAT+: Trump’s vaccine pivot overshadows food rule
Santé Bien-être
STAT+: Pharmalittle: We’re reading about an FDA rejection, 340B court battles, and more
Santé Bien-être
STAT+: A RAPID proposal for breakthrough coverage, and nurses push back on AI
Santé Bien-être
STAT+: Skylark Bio kicks off new gene therapy trial for deafness
Santé Bien-être
IRBs have a problem. Can North Star’s nonprofit model save it?
Santé Bien-être
Opinion: The new geography of abortion care
Santé Bien-être
Opinion: Burdensome Medicare GLP-1 program may keep patients from accessing $50 per month weight loss drugs
Santé Bien-être
STAT+: Nurses seek a seat at the table as they fight expanding clinical AI
Santé Bien-être
STAT+: Why is MoonLake Immunotherapeutics scared of releasing data on its drug candidate?
Santé Bien-être
Trump returns to controversial vaccine policy with order questioning childhood schedule
Santé Bien-être
STAT+: In surprise decision, FDA rejects radiopharma therapy expected to rival Novartis treatment
Santé Bien-être
FDA to require notice of additives in food supply for the first time
Santé Bien-être
STAT+: Ban prior auth? And hospitals cut jobs
Santé Bien-être
STAT+: FDA panel to weigh Grail’s Galleri test
Santé Bien-être
STAT+: Pharmalittle: We’re reading about a Sanofi drug shortage, a Jazz Pharma deal, and more
Santé Bien-être
STAT+: Sionna’s experimental cystic fibrosis pill falls flat in mid-stage trial
Santé Bien-être
STAT+: Heart failure drug from Tenax Therapeutics fails in pivotal study
Santé Bien-être
STAT+: Silence Therapeutics aims at Takeda with new data in rare blood cancer
Santé Bien-être
Opinion: We prepared for Ebola — but not this Ebola
Santé Bien-être
Opinion: How should states reach out to Medicaid enrollees affected by changes? Our research gives a hint
Santé Bien-être
STAT+: The promise of radiopharmaceuticals smacks into safety concerns
Santé Bien-être
Opinion: We prepared for Ebola — but not this Ebola
Santé Bien-être
STAT+: China tightens the reins on clinical trials, even as the U.S. looks for ways to replicate its rival’s speed
Santé Bien-être
STAT+: A shortage of two Sanofi medicines for Pompe disease rattles patients
Santé Bien-être
Opinion: Fauci doesn’t have the answers on Covid’s origins. China does
Santé Bien-être
STAT+: Up and down the ladder: The latest comings and goings
Santé Bien-être
STAT+: NIH plans to block international researchers on visas from accessing key funding avenue
Santé Bien-être
STAT+: Pharmalittle: We’re reading about Replimune’s melanoma drug, a Medicare policy change, and more
Santé Bien-être
Is the biotech capital of the world moving?
Santé Bien-être
A third clinic settles with DOJ over trans care
Santé Bien-être
STAT+: He grew up near Boston, went to Harvard, and worked at MIT. Why did he found his startup in California?
Santé Bien-être
Opinion: I was in my office when bullets hit the CDC. A year later, the agency remains under attack
Santé Bien-être
Opinion: AI won’t enhance physician autonomy. It will further diminish it
Santé Bien-être
STAT+: FDA approves Replimune melanoma drug previously rejected twice
Santé Bien-être